title: Improved Fetal Hemoglobin With mTOR Inhibitor-Based Immunosuppression in a Kidney Transplant Recipient With Sickle Cell Disease.
abstract: Fetal hemoglobin induction is a key point in the management of sickle cell disease (SCD). We report the case of a kidney transplant recipient with SCD who was treated with everolimus, a mammalian target of rapamycin inhibitor. At 10 months after initiating therapy, the patient's fetal hemoglobin level was dramatically increased (from 4.8% to 15%) and there was excellent tolerance to treatment.
authors.affiliation: Department of Vascular Medicine, CHU Rangueil, Toulouse, France.
authors.forename: N
authors.initials: N
authors.lastname: Gaudre
authors.affiliation: Department of Internal Medicine, Cancer University Institute of Toulouse-Oncopole, Toulouse, France.
authors.forename: P
authors.initials: P
authors.lastname: Cougoul
authors.affiliation: AP-HP, Groupe Hospitalier Henri Mondor-Albert Chenevier, Centre de Référence des Syndromes Drépanocytaires Majeurs, Créteil, France.|Laboratoire d'Excellence GRex, Département Hospitalo-Universitaire Ageing-Thorax-Vessels-Blood, Institut Mondor de Recherche Biomédicale, Université Paris-Est-Créteil, Créteil, France.|Service de Médecine Interne, AP-HP, Groupe Hospitalier Henri Mondor-Albert Chenevier, Créteil, France.
authors.forename: P
authors.initials: P
authors.lastname: Bartolucci
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.|Université Paul Sabatier, Toulouse, France.
authors.forename: G
authors.initials: G
authors.lastname: Dörr
authors.affiliation: Department of Vascular Medicine, CHU Rangueil, Toulouse, France.
authors.forename: A
authors.initials: A
authors.lastname: Bura-Riviere
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.|Université Paul Sabatier, Toulouse, France.|INSERM U1043, IFR-BMT, CHU Purpan, Toulouse, France.
authors.forename: N
authors.initials: N
authors.lastname: Kamar
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
authors.forename: A
authors.initials: A
authors.lastname: Del Bello
mesh_terms: D000328:Adult; D000755:Anemia, Sickle Cell / Q000601:surgery*; D000068338:Everolimus / Q000627:therapeutic use*; D005319:Fetal Hemoglobin / Q000378:metabolism*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008297:Male; D011379:Prognosis; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D066027:Transplant Recipients
chemical_list: D007166:Immunosuppressive Agents; D005319:Fetal Hemoglobin; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases
keywords: anemia; clinical research/practice; everolimus; immunosuppressant; kidney disease; kidney transplantation/nephrology; mechanistic target of rapamycin